MEI Pharma halts voruciclib clinical development, begins strategic alternatives review

Lite Strategy, Inc.

Board unanimously decided to evaluate strategic alternatives including potential transactions or orderly wind-down.
Clinical development of voruciclib discontinued; only certain non-clinical activities will continue.
Company intends to maximize value of its assets; no specific timeline or deal announced.
Corporate presentation attached as Exhibit 99.1 details voruciclib program status.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.